Ads
related to: crh and cortisol interaction treatment side effects for bladder cancer- Dosing Information
See Dosing & Administration
Info For HCPs.
- Important Safety Info
See Safety Info & Learn
About Adverse Reactions.
- Clinical Trial Data
View Clinical Trial Results
And See Efficacy Data.
- Full Prescribing Info
View Prescribing Information
On The Official HCP Website.
- Dosing Information
Search results
Results From The WOW.Com Content Network
A Corticotropin-releasing hormone antagonist (CRH antagonist) is a specific type of receptor antagonist that blocks the receptor sites for corticotropin-releasing hormone, also known as corticotropin-releasing factor (CRF), which synchronizes the behavioral, endocrine, autonomic, and immune responses to stress by controlling the hypothalamic-pituitary-adrenal axis (HPA axis). [1]
Corticotropin-releasing hormone (CRH) (also known as corticotropin-releasing factor (CRF) or corticoliberin; corticotropin may also be spelled corticotrophin) is a peptide hormone involved in stress responses. It is a releasing hormone that belongs to corticotropin-releasing factor family. In humans, it is encoded by the CRH gene. [5]
Antalarmin (CP-156,181) is a drug that acts as a CRH1 antagonist. Corticotropin-releasing hormone (CRH), also known as Corticotropin-releasing factor, is an endogenous peptide hormone released in response to various triggers such as chronic stress and drug addiction.
CRH is a 41-amino-acid peptide hormone that is secreted by the parvocellular neurosecretory cells, which are found within the paraventricular nucleus of the hypothalamus. [9] Stimuli for the release of CRH from the hypothalamus include: Forskolin [10] Interleukin-6 [10] Pituitary adenylate cyclase-activating peptide (PACAP) [10] Stress or trauma
Cisplatin and gemcitabine treatment may be associated with less severe side effects. [5] Up to half of people with bladder cancer are not able to take these chemotherapy treatments due to their overall health. Taxanes or vinflunine have been used as second-line therapy (after progression on a platinum containing chemotherapy). [16]
11β-Hydroxylase (CYP11B1) inhibitors such as amphenone B, [20] etomidate, [16] ketoconazole, [16] metyrapone, [16] mitotane, [16] and osilodrostat [25] inhibit the production of the potent corticosteroids cortisol, corticosterone, and aldosterone from the less potent corticosteroids 11-deoxycorticosterone and 11-deoxycortisol and are used in ...